Hepalink to acquire USA’s Scientific Protein Laboratories

China’s Shenzhen Hepalink Pharmaceutical (002399.SZ) has entered into a stock purchase agreement to acquire USA-based Scientific Protein Laboratories, a leading global, independent manufacturer and supplier of active pharmaceutical ingredients (APIs).

Under the terms of the accord, Hepalink has agreed to acquire SPL for $337.5 million in cash plus certain contingent payments. The transaction is currently expected to close during the first half of 2014.

The US firm was largely owned by American Capital, when the publicly listed investment vehicle took an 87% ownership in 2006 by investing a total of $135.66 million in the company in the forms of senior term A loan, senior second lien loan, senior and junior subordinated debt and equity.